Novotech, a global contract research organization (CRO), has announced the appointment of Dr. Yooni Kim as Executive President of Asia Pacific (APAC), effective September 1, 2024. This move reflects Novotech’s dedication to expanding its global reach and enhancing its operational capabilities. As a leading CRO across all phases of clinical trials, the company aims to further establish its presence in key regions like the United States, Europe, Mainland China, and the Asia Pacific.
Dr. Kim, who brings over 25 years of experience in academic research, CROs, and pharmaceutical clinical trials, has been instrumental in the growth of the CRO industry in the APAC region. She joined Novotech in 2016 as Executive Director and played a crucial role in expanding its business in Asia. Following the 2019 merger with PPC, she became Vice President of Global Clinical Services, where she led the global clinical services team and coordinated Novotech’s clinical trial strategies with stakeholders worldwide. Dr. Kim holds a Bachelor’s in Pharmacy from Ewha Womans University and a PhD in Preventive Medicine from Seoul National University.
“We are thrilled to have Dr. Yooni Kim lead our Asia Pacific operations,” said Dr. John Moller, CEO of Novotech. “Her profound knowledge of the clinical research landscape in Asia and her leadership will be essential as we strengthen our position in this critical market.”
As Executive President of APAC, Dr. Kim will provide strategic leadership across the region, ensuring smooth operations and guiding Novotech’s growth. “I am excited to take on this role and will prioritize customer needs while driving initiatives that enhance Novotech’s capabilities in the Asia Pacific region,” said Dr. Kim. “I plan to maintain strong relationships with key opinion leaders, regulatory bodies, and clinical trial institutions, which will benefit our clients’ clinical programs.”
Dr. Moller emphasized the importance of the APAC market for Novotech, noting that Dr. Kim’s appointment will ensure strong leadership focused on delivering reliable outcomes for the company’s clinical trial programs.
In addition to her regional role, Dr. Kim will join Novotech’s Executive Committee, contributing to the company’s overall strategic direction and global initiatives. Novotech remains committed to optimizing its organizational structure and supporting its vision of becoming a biotechnology partner at all stages of development.
